Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent… Read more
Wave Life Sciences Ltd (WVE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.359x
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has a cash flow conversion efficiency ratio of -0.359x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.67 Million) by net assets ($124.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wave Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Wave Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Wave Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wave Life Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SHOU. HLDGS. LTD. (BL)
F:SHVA
|
N/A |
|
Guangdong Shenglu Telecommunication Tech Co Ltd
SHE:002446
|
-0.007x |
|
Perella Weinberg Partners
NASDAQ:PWP
|
0.295x |
|
Indosat Tbk
JK:ISAT
|
0.164x |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
0.047x |
|
Wilhelm Wilhelmsen Holding ASA
LSE:0P0T
|
0.009x |
|
Zhejiang Windey Co Ltd
SHE:300772
|
0.144x |
|
Sinochem International Corp
SHG:600500
|
0.046x |
Annual Cash Flow Conversion Efficiency for Wave Life Sciences Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Wave Life Sciences Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $209.51 Million | $-151.03 Million | -0.721x | -47.02% |
| 2023-12-31 | $39.63 Million | $-19.43 Million | -0.490x | -117.30% |
| 2022-12-31 | $-45.09 Million | $-127.78 Million | 2.834x | +203.48% |
| 2021-12-31 | $32.50 Million | $-88.99 Million | -2.738x | -114.04% |
| 2020-12-31 | $90.65 Million | $-115.98 Million | -1.279x | +51.33% |
| 2019-12-31 | $71.61 Million | $-188.23 Million | -2.629x | -743.37% |
| 2018-12-31 | $73.35 Million | $-22.86 Million | -0.312x | +47.92% |
| 2017-12-31 | $139.81 Million | $-83.67 Million | -0.598x | -153.23% |
| 2016-12-31 | $134.86 Million | $-31.87 Million | -0.236x | -189.57% |
| 2015-12-31 | $153.49 Million | $-12.53 Million | -0.082x | +96.26% |
| 2014-12-31 | $2.03 Million | $-4.43 Million | -2.184x | -577.29% |
| 2013-12-31 | $-7.76 Million | $-3.55 Million | 0.457x | -- |